Summary

The Small Molecule Drug Discovery market is anticipated to grow from US$ 50.93 billion in 2023 and is projected to reach US$ 106.77 billion by 2031; it is expected to register a CAGR of 9.7% during 2023–2031. Flourishing pharmaceutical industry with surge in R&D activities and growing inclination toward outsourcing are contributing to the small molecule drug discovery market growth. However, high drug development costs hamper market growth. Further, the growing adoption of artificial intelligence in drug discovery is expected to bring new small molecule drug discovery market trends in the coming years.

North America accounted for a major share of the global small molecule drug discovery market in 2023. The North America small molecule drug discovery market is segmented into the US, Canada, and Mexico. Increasing research and development by pharmaceutical and biotechnology companies in discovering novel drugs, growing investments in pharmaceuticals, and prevalence of cancer are among the factors that are projected to accelerate the growth of the North America small molecule drug discovery market. The US is one of the most developed countries in North America. The increasing prevalence of chronic diseases such as cardiovascular diseases and cancer primarily drives the market growth in the country. As per the American Cancer Society, in 2024, ~2 million people are projected to suffer from new cancer cases, and ~611,000 death cases are expected to be registered in the US. Owing to this scenario, the US health system witnesses massive investments in research and developments for novel drug molecules. Further, a strong drug pipeline, along with therapeutic area approvals for small molecule drugs, is expected to drive the regional market. Apart from the rising number of approved drugs, increasing awareness of advanced therapeutics is likely to be responsible for the growth of the small molecule drug discovery market during the forecast period.

The growth of the Canada small molecule drug discovery market is attributed to increasing government initiatives and growing cancer prevalence, as well as strategic initiatives by the major players. Canadians are able to deal with a variety of medical conditions due to the availability of innovative treatment options. The rising adoption of small molecule medicines in Canadian healthcare is likely to continue to boost the market growth over the coming years.

As per the Government of Canada, the country ranks ninth among the largest pharmaceutical markets in the world in terms of sales value. Innovative pharmaceutical companies, drug manufacturers, contract research organizations (CROs), and small- and medium-sized biopharmaceutical companies are among the major enablers of such a huge sales value. According to Statistics Canada 2020, 6,280 companies were operating in Canada. The pharmaceutical sector accounts for 41%, and the research and development sector accounts for 31% of its overall healthcare sector. Thus, the rapidly growing pharmaceutical and biopharmaceutical industries generate a huge demand for small molecule drug discovery in Canada.

Increasing Small Molecule-Based Pipeline to Provide Market Opportunities in Future

The pharmaceutical industry is continually evolving and there is always a need for new, innovative therapeutic approaches in the treatment of various chronic indications. Small molecule-based drug approvals have been increased in the past five years owing to their effectiveness against a wide range of indications. Small molecule drug candidate-based pipelines are growing for a wide range of therapeutic applications, including oncology, hypertension, diabetes, and inflammatory disorders. Many big and small pharmaceutical companies are engaged in the development of several small-molecule drugs.

The growing pipeline of small molecule-based drugs for various indications is, in turn, boosting drug discovery activities across the industry.

Compound Name Compound Type Company Name Clinical Phase Indication

PF-06821497 Small Molecule Pfizer Inc. Phase 1 Cancer

PF-06873600 Small Molecule Pfizer Inc. Phase 1 Breast Cancer Metastatic

PF-06939999 Small Molecule Pfizer Inc. Phase 1 Solid Tumors

PF-06952229 Small Molecule Pfizer Inc. Phase 1 Cancer

PF-06826647 Small Molecule Pfizer Inc. Phase 1 Ulcerative Colitis

PF-07038124 Small Molecule Pfizer Inc. Phase 1 Atopic Dermatitis

PF-06842874 Small Molecule Pfizer Inc. Phase 1 Pulmonary Arterial Hypertension

PF-06865571 Small Molecule Pfizer Inc. Phase 1 Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis

PF-06882961 Small Molecule Pfizer Inc. Phase 1 Diabetes Mellitus-Type 2, Obesity

PF-07081532 Small Molecule Pfizer Inc. Phase 1 Diabetes Mellitus-Type 2, Obesity

R835 Small Molecule Rigel Pharmaceuticals, Inc. Phase 1 Inflammatory

Disorders

R552 Small Molecule Rigel Pharmaceuticals, Inc. Phase 1 Inflammatory

Disorders

SY-1425 Small Molecule Syros Pharmaceuticals, Inc. Phase 2 AML

Source: Company News and The Insight Partner Analysis

 

Small Molecule Drug Discovery Market: Competitive Landscape and Key Developments

Bristol-Myers Squibb Co, Merck KGaA, GSK Plc, Boehringer Ingelheim International GmbH, Thermo Fisher Scientific Inc, ICON Plc, Danaher Corp, Charles River Laboratories International Inc, Oncodesign Services, and Revvity Inc are among the key companies operating in the small molecule drug discovery market.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Centre for the Study of Drug Development are among the primary and secondary sources referred to while preparing the small molecule drug discovery market report.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance.
1.2 Market Segmentation.
2. Executive Summary
2.1 Key Insights.
3. Research Methodology
3.1 Secondary Research.
3.2 Primary Research.
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.1 Developing base number:
3.2.2 Data Triangulation:
3.2.3 Country level data:
4. Small Molecule Drug Discovery Market Landscape
4.1 Overview.
4.2 PEST Analysis.
5. Small Molecule Drug Discovery Market – Key Market Dynamics
5.1 Small Molecule Drug Discovery Market – Key Market Dynamics.
5.2 Market Drivers.
5.2.1 Flourishing Pharmaceutical Industry with Surge in R&D Activities.
5.2.2 Growing Inclination Toward Outsourcing.
5.3 Market Restraints.
5.3.1 High Drug Development Cost
5.4 Market Opportunities.
5.4.1 Increasing Small Molecule-Based Pipeline.
5.5 Future Trends.
5.5.1 Growing Adoption of Artificial Intelligence in Drug Discovery.
5.6 Impact of Drivers and Restraints:
6. Small Molecule Drug Discovery Market – Global Market Analysis
6.1 Small Molecule Drug Discovery Market Revenue (US$ Million), 2021–2031.
6.2 Small Molecule Drug Discovery Market Forecast Analysis.
7. Small Molecule Drug Discovery Market Analysis – by Therapeutic Area
7.1 Oncology.
7.1.1 Overview.
7.1.2 Oncology: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Central Nervous System..
7.2.1 Overview.
7.2.2 Central Nervous System: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Cardiovascular
7.3.1 Overview.
7.3.2 Cardiovascular: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Respiratory.
7.4.1 Overview.
7.4.2 Respiratory: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Orthopedics.
7.5.1 Overview.
7.5.2 Orthopedics: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Immunology.
7.6.1 Overview.
7.6.2 Immunology: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Rare Diseases.
7.7.1 Overview.
7.7.2 Rare Diseases: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
7.8 Other Therapeutic Areas.
7.8.1 Overview.
7.8.2 Other Therapeutic Areas: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
8. Small Molecule Drug Discovery Market Analysis – by Process or Phase
8.1 Target Discovery.
8.1.1 Overview.
8.1.2 Target Discovery: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Target Validation.
8.2.1 Overview.
8.2.2 Target Validation: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Lead Generation and Refinement
8.3.1 Overview.
8.3.2 Lead Generation and Refinement: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Preclinical Development
8.4.1 Overview.
8.4.2 Preclinical Development: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9. Small Molecule Drug Discovery Market – Geographical Analysis
9.1 North America.
9.1.1 North America Small Molecule Drug Discovery Market Overview.
9.1.2 North America: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.1.3 North America: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Therapeutic Area.
9.1.4 North America: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Process or Phase.
9.1.5 North America: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Country.
9.1.5.1 United States: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.1.5.1.1 United States: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.1.5.1.2 United States: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.1.5.2 Canada: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.1.5.2.1 Canada: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.1.5.2.2 Canada: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.1.5.3 Mexico: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.1.5.3.1 Mexico: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.1.5.3.2 Mexico: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.2 Europe
9.2.1 Europe Small Molecule Drug Discovery Market Overview.
9.2.2 Europe: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.2.3 Europe: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Therapeutic Area.
9.2.4 Europe: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Process or Phase.
9.2.5 Europe: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Country.
9.2.5.1 Germany: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.2.5.1.1 Germany: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.2.5.1.2 Germany: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.2.5.2 France: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.2.5.2.1 France: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.2.5.2.2 France: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.2.5.3 United Kingdom: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.2.5.3.1 United Kingdom: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.2.5.3.2 United Kingdom: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.2.5.4 Italy: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.2.5.4.1 Italy: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.2.5.4.2 Italy: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.2.5.5 Spain: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.2.5.5.1 Spain: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.2.5.5.2 Spain: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.2.5.6 Rest of Europe: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.2.5.6.1 Rest of Europe: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.2.5.6.2 Rest of Europe: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.3 Asia Pacific.
9.3.1 Asia Pacific Small Molecule Drug Discovery Market Overview.
9.3.2 Asia Pacific: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.3.3 Asia Pacific: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Therapeutic Area.
9.3.4 Asia Pacific: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Process or Phase.
9.3.5 Asia Pacific: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Country.
9.3.5.1 Japan: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.3.5.1.1 Japan: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.3.5.1.2 Japan: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.3.5.2 China: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.3.5.2.1 China: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.3.5.2.2 China: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.3.5.3 India: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.3.5.3.1 India: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.3.5.3.2 India: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.3.5.4 South Korea: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.3.5.4.1 South Korea: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.3.5.4.2 South Korea: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.3.5.5 Australia: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.3.5.5.1 Australia: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.3.5.5.2 Australia: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.3.5.6 Rest of APAC: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.3.5.6.1 Rest of APAC: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.3.5.6.2 Rest of APAC: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.4 Middle East & Africa.
9.4.1 Middle East & Africa Small Molecule Drug Discovery Market Overview.
9.4.2 Middle East & Africa: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.4.3 Middle East & Africa: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Therapeutic Area.
9.4.4 Middle East & Africa: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Process or Phase.
9.4.5 Middle East & Africa: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Country.
9.4.5.1 Saudi Arabia: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.4.5.1.1 Saudi Arabia: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.4.5.1.2 Saudi Arabia: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.4.5.2 United Arab Emirates: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.4.5.2.1 United Arab Emirates: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.4.5.2.2 United Arab Emirates: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.4.5.3 South Africa: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.4.5.3.1 South Africa: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.4.5.3.2 South Africa: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.4.5.4 Rest of Middle East & Africa: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.4.5.4.1 Rest of Middle East & Africa: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.4.5.4.2 Rest of Middle East & Africa: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.5 South & Central America.
9.5.1 South & Central America Small Molecule Drug Discovery Market Overview.
9.5.2 South & Central America: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.5.3 South & Central America: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Therapeutic Area.
9.5.4 South & Central America: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Process or Phase.
9.5.5 South & Central America: Small Molecule Drug Discovery Market – Revenue and Forecast Analysis – by Country.
9.5.5.1 Brazil: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.5.5.1.1 Brazil: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.5.5.1.2 Brazil: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.5.5.2 Argentina: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.5.5.2.1 Argentina: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.5.5.2.2 Argentina: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
9.5.5.3 Rest of South & Central America: Small Molecule Drug Discovery Market – Revenue and Forecast to 2031 (US$ Million)
9.5.5.3.1 Rest of South & Central America: Small Molecule Drug Discovery Market Breakdown, by Therapeutic Area.
9.5.5.3.2 Rest of South & Central America: Small Molecule Drug Discovery Market Breakdown, by Process or Phase.
10. Industry Landscape
10.1 Overview.
11. Company Profiles
11.1 Bristol-Myers Squibb Co.
11.1.1 Key Facts.
11.1.2 Business Description.
11.1.3 Products and Services.
11.1.4 Financial Overview.
11.1.5 SWOT Analysis.
11.1.6 Key Developments.
11.2 Merck KGaA.
11.2.1 Key Facts.
11.2.2 Business Description.
11.2.3 Products and Services.
11.2.4 Financial Overview.
11.2.5 SWOT Analysis.
11.2.6 Key Developments.
11.3 GSK Plc.
11.3.1 Key Facts.
11.3.2 Business Description.
11.3.3 Products and Services.
11.3.4 Financial Overview.
11.3.5 SWOT Analysis.
11.3.6 Key Developments.
11.4 Thermo Fisher Scientific Inc.
11.4.1 Key Facts.
11.4.2 Business Description.
11.4.3 Products and Services.
11.4.4 Financial Overview.
11.4.5 SWOT Analysis.
11.4.6 Key Developments.
11.5 ICON Plc.
11.5.1 Key Facts.
11.5.2 Business Description.
11.5.3 Products and Services.
11.5.4 Financial Overview.
11.5.5 SWOT Analysis.
11.5.6 Key Developments.
11.6 Danaher Corp.
11.6.1 Key Facts.
11.6.2 Business Description.
11.6.3 Products and Services.
11.6.4 Financial Overview.
11.6.5 SWOT Analysis.
11.6.6 Key Developments.
11.7 Charles River Laboratories International Inc.
11.7.1 Key Facts.
11.7.2 Business Description.
11.7.3 Products and Services.
11.7.4 Financial Overview.
11.7.5 SWOT Analysis.
11.7.6 Key Developments.
11.8 Oncodesign Services.
11.8.1 Key Facts.
11.8.2 Business Description.
11.8.3 Products and Services.
11.8.4 Financial Overview.
11.8.5 SWOT Analysis.
11.8.6 Key Developments.
11.9 Revvity Inc.
11.9.1 Key Facts.
11.9.2 Business Description.
11.9.3 Products and Services.
11.9.4 Financial Overview.
11.9.5 SWOT Analysis.
11.9.6 Key Developments.
11.10 Boehringer Ingelheim International GmbH.
11.10.1 Key Facts.
11.10.2 Business Description.
11.10.3 Products and Services.
11.10.4 Financial Overview.
11.10.5 SWOT Analysis.
11.10.6 Key Developments.
12. Appendix
12.1 About The Insight Partners.
12.2 Glossary of Terms.